Celebrating India’s independence, enterprise and progress
news

'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week

Jan 6, 2026 · Source: cision
'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week

PISCATAWAY, N.J., Jan. 6, 2026 -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech Global Forum, scheduled for January 14, 2026, at the San Francisco Marriott Marquis, with both in-person and virtual attendance options available.

GenScript, Scripting Possibilities Logo

Now in its fifth year, GenScript Biotech Global Forum has become a convening platform to push the boundaries of what's possible for the global biotech ecosystem. Held alongside the annual J.P. Morgan Healthcare Conference week, the Forum brings together the scientists, innovators, investors and decision-makers to discuss the future of biotechnology – where discovery, computation and therapeutic development converge to turn scientific possibilities into patient impact.

Under the theme 'Scripting Possibilities', this year's Forum will explore how transformative advancements, computational revolutions and emerging technologies redefine what is possible in cell and gene therapies (CGTs) and next-generation biotherapeutics. Attendees will engage in forward-looking discussions on the technologies and collaborations shaping next-generation biotherapeutics and accelerating the path from idea to impact.

"The Global Forum has become a central gathering point for leaders driving progress across the biotech ecosystem," said Sherry Shao, CEO, GenScript Biotech Corp. "We are proud to bring this community together in San Francisco once again. Our mission is to empower researchers and companies end-to-end – with integrated technologies, platforms and expertise – from discovery to development and manufacturing through our Life Science Group and ProBio businesses. GenScript is confidently expanding its role in the industry to turn bold scientific ideas into real therapeutic impact and to accelerate the delivery of these innovations to patients worldwide."

Two Visionaries Defining the Next Chapter in Biotech

The 5th Annual Biotech Global Forum will feature two globally recognized keynote speakers whose work is redefining the boundaries of science, computation, and therapeutic innovation:

  • David Baker, PhD, Director, Institute for Protein Design; Professor of Biochemistry, University of Washington; Investigator, Howard Hughes Medical Institute; Nobel Laureate in Chemistry (2024). Dr. Baker is the pioneer of computational protein design, creating new molecules and therapeutic modalities once thought impossible and fundamentally redefining how medicines can be engineered.
  • Eric Horvitz, PhD, MD, Chief Scientific Officer, Microsoft. Dr. Horvitz is a trailblazer in artificial intelligence and responsible AI, driving advancements that are influencing how computation accelerates biomedical research, drug development and clinical decision-making at global scale.

Together, these leaders represent the convergence of biology and intelligence – where molecules are designed with algorithms and insight is amplified through AI.

Forum Highlights:

  • Keynote & Fireside Conversation: A forward-looking discussion on computational protein design, AI and the future architecture of therapeutic innovation.
  • Insight-Driven Panel Sessions: Exploring the next frontier in cell and gene therapy, AI-enabled drug discovery and the global forces shaping biotech's evolution.
  • Technology Showcase: Featuring GenScript's next-generation Dark Lab and GenGenius+ automation platform, demonstrating how AI and automation are transforming laboratory workflows.
  • Advanced Therapy Spotlight: Perspectives on translating CGT innovation into scalable, clinical-ready solutions, informed by GenScript's end-to-end capabilities, including ProBio's advanced biologics and cell and gene therapy manufacturing expertise.
  • High-Impact Networking: Connecting scientists, biotech leaders, investors and technology partners to spark collaboration and unlock new opportunities throughout the program and evening reception.

"Biotechnology is at an inflection point – where speed, precision and collaboration are no longer optional," said Ray Chen, PhD, President, GenScript Life Science Group. "The Global Forum is designed to bring together the leaders scripting what comes next, and to explore ways of pushing the boundaries of what's seemingly impossible. This year's program reflects a powerful convergence – discovery science, computational intelligence and therapeutic development coming together to script what's possible next. When these forces align, scientific discoveries move faster, scale smarter and reach patients sooner."

Registration for the GenScript Biotech Global Forum is now open.

For more information and to register, please visit GenScript's official website.

About GenScript Biotech Corporation

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript supports customers across the full innovation lifecycle - from early discovery and automation-driven research to advanced biologics and manufacturing - including through its ProBio business. GenScript has a team of over 5,700 employees and has served more than 200,000 customers across over 100 countries and regions.

Learn more here: https://www.genscript.com.

Media Contact

Stefanie Tuck

CG Life

stuck@cglife.com

GenScript Biotech Global Forum logo

Photo - https://mma.prnewswire.com/media/2855189/GenScript_Logo.jpg

Photo - https://mma.prnewswire.com/media/2855190/GenScript_BGF.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/scripting-possibilities-in-biotechnology-global-innovators-converge-in-san-francisco-for-genscripts-5th-annual-biotech-forum-during-jpm-week-302653503.html

Comments (0)

Login to join the conversation

Login / Register

No comments yet. Be the first to comment!

More to Read

Nexteer Reports Record First-Half 2026 Results
news
Aug 12, 2026 1 min

Nexteer Reports Record First-Half 2026 Results

Customer Wins, Technology Milestones and Digital Transformation Advance Motion Control Leadership AUBURN HILLS, Mich. , Aug. 12, 2026 -- Nexteer Automotive (HK 1316) today announced its 2026 interim results, reporting record first-half performance driven by above-market growth, strategic customer wins and continued advancement of next-generation motion control technologies. Revenue for the period was US 2.3 billion, up 4% compared with the first half of 2025, while total customer bookings reached US 3.3 billion. New and conquest business represented 43% of total bookings, and China domestic OEMs (COEMs) accounted for approximately US 1.0 billion, or 30%, reinforcing Nexteer s position as a trusted motion control partner to OEMs across major global markets. As Nexteer marks its 120th anniversary, the company continues to build on its legacy of innovation while accelerating digital transformation to help OEMs improve speed, efficiency, quality and cost competitiveness in an increasingly complex mobility landscape.

Mach Travel Solutions Ltd Q1 FY27 Revenue Jumps 538% YoY to ₹144.33 Crore
news
Aug 12, 2026 1 min

Mach Travel Solutions Ltd Q1 FY27 Revenue Jumps 538% YoY to ₹144.33 Crore

PAT rises 307% YoY as diversified growth strategy gains momentum NEW DELHI , Aug. 12, 2026 -- Mach Travel Solutions Limited (BSE: MACHLTD), formerly known as Mach Conferences & Events Limited, announced its unaudited Q1 FY27 results. Revenue from Operations stood at 144.33 crore, up 538% YoY, while PAT stood at 6.17 crore, up 307% YoY. The Company also recorded Gross Merchandise Value (GMV) of approximately 252 crore, reflecting the scale of travel transactions handled across its diversified platform.

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results
news
Aug 12, 2026 1 min

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

CAMBRIDGE, Mass. , Aug. 12, 2026 -- Cypherpunk Technologies Inc., (Nasdaq: CYPH) ( Cypherpunk ), today reported financial results for the second quarter ended June 30, 2026. In the second quarter, Cypherpunk built upon the momentum established earlier this year through the disciplined execution of our Zcash digital asset treasury strategy, increasing our treasury holdings to 323,394.38 ZEC, and welcoming Dev Ojha, founder of Valar Group, as an Advisor, said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. Our Leap Therapeutics subsidiary reached alignment with the FDA on a proposed Phase 3 trial in a DKK1-high, second-line, metastatic colorectal cancer population, with objective response rate as the primary endpoint to support accelerated approval and overall survival to support full approval in the United States and registration globally. We are conducting a strategic process to determine the best path to advance sirexatamab, whether as an independently financed spin-out company or with a partner who shares our commitment to cancer patients.

Context Labs Enters Multi-Year Agreement with Trafigura and Acquires Kinertic to Power Carbon-Informed Commodities Trading
news
Aug 12, 2026 1 min

Context Labs Enters Multi-Year Agreement with Trafigura and Acquires Kinertic to Power Carbon-Informed Commodities Trading

Industrial AI platform will connect primary emissions data to operating entities and trading desks in oil, gas and metals across Trafigura s global portfolio AMSTERDAM , Aug. 12, 2026 -- Context Labs B.V. ( Context Labs ), the industrial AI infrastructure company, today announced three connected transactions with Trafigura PTE Ltd ( Trafigura ): the acquisition of Agora (Europe) Limited and its Kinertic carbon-intelligence platform, developed by Trafigura; a strategic equity investment by Trafigura in Context Labs; and a multi-year master services and platform license agreement under which Trafigura will deploy the combined platform across its commodity trading desks, including oil, gas, and metals.

HTX Releases July Performance Report: TradFi Zone Evolves, Reaching Record Daily Trading Volume
news
Aug 12, 2026 1 min

HTX Releases July Performance Report: TradFi Zone Evolves, Reaching Record Daily Trading Volume

APIA, Samoa , Aug. 12, 2026 -- As market narratives shift rapidly, investors increasingly demand broader asset allocation and higher capital efficiency. The ability to capture market opportunities instantly, alongside solid product offerings, earnings, and services, serves as the most direct benchmark for evaluating a trading platform. In July 2026, staying true to its User First principle, HTX delivered a multi-dimensional performance report marked by a 15% month-to-month growth in new registered users, driven by continuous optimization across listings, trading tools, earning products, campaign operations, and ecosystem building.

nubia Neo 5 Max with 7.5-Inch Display Lands as a New PadPhone Category
news
Aug 12, 2026 1 min

nubia Neo 5 Max with 7.5-Inch Display Lands as a New PadPhone Category

SHENZHEN, China , Aug. 12, 2026 -- nubia, a highly personalized and lifestyle smartphone brand committed to bringing pro-level gaming to everyone, announced the global rollout of nubia Neo 5 Max, introducing a new PadPhone category that combines the expansive viewing experience of a compact tablet with the portable control of a gaming console. Built around a segment-leading 7.5-inch display, nubia Neo 5 Max brings together pad-level immersion, console-level control, immersive audio-visual feedback and AI-powered gaming assistance in one versatile device for gaming, entertainment and everyday productivity.

Compunnel Doubles Down on its Digital Business to Lead the Enterprise AI Shift
news
Aug 12, 2026 1 min

Compunnel Doubles Down on its Digital Business to Lead the Enterprise AI Shift

The AI-native digital engineering business unifies four engineering disciplines under its AI-OS framework to help enterprises move from AI pilots to measurable, at-scale business value. NOIDA, India, Aug. 12, 2026 -- Compunnel today announced the restructuring of Compunnel Digital , its digital engineering business, repositioned as an AI-native engineering partner for global enterprises. The repositioning consolidates four engineering disciplines Applied AI Engineering, Data Platforms & Intelligence, Cloud & Platform Engineering, and Autonomous Quality Engineering under AI-OS , the company s integrated enterprise delivery framework, to help clients move from fragmented AI pilots to industrialized, measurable business value.

BASF Agricultural Solutions invests in new Climate Center at its headquarters to strengthen research capabilities
news
Aug 12, 2026 1 min

BASF Agricultural Solutions invests in new Climate Center at its headquarters to strengthen research capabilities

State-of-the-art research facility at Limburgerhof site responds to increasing regulatory and research demands Purpose-built facility will enable controlled, reproducible ecotoxicology studies to support the registration of crop protection products worldwide Investment supports company s innovation strategy LIMBURGERHOF, Germany , Aug. 12, 2026 -- BASF Agricultural Solutions is investing a low double-digit million-euro amount in a new Climate Center at its headquarters in Limburgerhof, Germany. The purpose-built facility will strengthen the company s research and regulatory capabilities and support the generation of scientific data required for the registration of crop protection products worldwide.